Staying on top of new medication therapy options for your consumers living with schizophrenia can be difficult. Learn how the new FDA-approved medication, Cobenfy – approved on September 26, 2024 – can help support the people you serve.
1. Cobenfy is the first in a new class of antipsychotic medications targeting muscarinic receptors and an alternative to D2 dopamine receptor antagonists not associated with the adverse effects of EPS, weight gain, or somnolence.
2. Cobenfy (xanomeline-trospium chloride) is a twice-daily oral medication with a novel mechanism of action.
3. Cobenfy combines xanomeline and trospium. Xanomeline targets the central nervous system (CNS) muscarinic receptors (M1 and M4 receptor agonist) while trospium is a muscarinic receptor antagonist working peripherally to reduce side effects.
4. While traditional antipsychotic medications primarily target dopamine receptors in the brain, Cobenfy preferentially activates the M1 and M4 neuroreceptors.
5. In data from the EMERGENT trial, Cobenfy demonstrated effectiveness in reducing schizophrenia symptoms with minimal adverse events. The most common side effects noted were gastrointestinal, such as nausea, vomiting, constipation and diarrhea.
For more information or questions on availability, contact your local Genoa pharmacy team.
Hear from industry experts
Have questions or want to learn more about Cobenfy and other emerging drug trends?
About the author
Kim Cordova, PharmD, serves as the director of Genoa’s procurement team, overseeing clinical procurement and trade relations. She plays a key role in ensuring the availability of pharmaceutical products and supports Genoa’s pharmacy teams to ensure they are well-equipped to deliver the highest quality care to the communities they serve.
For general information on Cobenfy: https://www.cobenfy.com/home.html
This information was accurate at the time of posting.
